|
Program Description
|
| The conference will feature distinguished speakers covering a broad spectrum of topics
ranging from basic science to clinical therapeutics. Presenters and discussants will explore current
issues and debate controversial topics. Case presentations will be given by the faculty and the
audience will participate by an interactive audience response system to stimulate discussion on
diagnosis and management. This program should be of interest to professionals actively engaged
clinically or scientifically in all facets of GI cancer research and care, including oncologists,
surgeons, radiologists, general scientists, fellows, young investigators, nurses and pharmacists.
|
| |
|
Educational Objectives
|
| After attending this activity, the participant will demonstrate the ability to: |
 |
Identify recent advances and innovations in the
treatment of GI malignancies within the past 12 months |
|
Describe emerging evidence from current clinical trials that
may impact treatment decision making in GI oncology |
|
Formulate a multi-modal approach to the treatment of GI
cancers including Gastric, HCC, Cholangiocarcinoma, Pancreatic and Colorectal Cancers
|
|
Understand the latest data on integrating multi-modality
treatment for all stages of GI malignancies |
|
| |
|
CME Accreditation and Designation Statement
|
This activity has been planned and implemented in accordance with the accreditation
requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME)
through the joint providership of The University of Kansas Medical Center Office of Continuing
Medical Education and the International Society of Gastrointestinal Oncology.
The University of Kansas Medical Center Office of Continuing Medical Education is accredited by the
ACCME to provide continuing medical education for physicians.
University of Kansas Medical Center Continuing Education designates this live activity for a maximum
of 12.25 AMA PRA Category 1 Credit(s)�. Physicians should claim only the credit commensurate
with the extent of their participation in the activity. |
|
Contributors Acknowledgments
|
These organizations have generously supported this symposium and we acknowledge them with sincerest
appreciation:
Array, Bayer, Boston Biomedical, Celgene, Eisai, Exelixis, Genentech, Incyte, Ipsen, Lilly,
Novocure, Pfizer,
Sirtex, Taiho, Varian.
|
Established 2003